Literature DB >> 2195055

A human IgG 3 is opsonic in vitro against type III group B streptococci.

J S Kim1, K S Kim, C A Wass, J A Short, D C Heiner.   

Abstract

Preparations of IgG 3 isolated by absorption of IgG 1, IgG 2, and IgG 4 from a human iv immunoglobulin with protein A-Sepharose were evaluated for their opsonic activities against type III group B streptococcal (GBS) strains. The resulting preparations were free of IgG 1 and IgG 2 and contained only trace amounts of IgG 4 (less than 2% of total IgG). These IgG 3 preparations exhibited excellent opsonic activities against type III GBS strains, similar to those of the unfractionated iv immunoglobulin (based on total IgG concentrations in the opsonic assays). In contrast, preparations of IgG 1, 2, and 4 eluted from protein A-Sepharose with 2 M acetic acid and 7 M urea were significantly less effective in enhancing phagocytosis and killing of type III GBS than IgG 3 preparations or iv immunoglobulin. The reasons for excellent opsonic activity of IgG 3 preparations as well as for decreased opsonic activity of IgG 1, 2, and 4 preparations are not clear. Perhaps alteration of IgG by lower pH and high concentrations of urea may have impaired the functional activity of IgG 1, 2, and 4 preparations. The significant finding of this study is the first demonstration of the excellent opsonic activity of IgG 3, emphasizing the importance of having intact IgG 3 in commercial immunoglobulin preparations used in prophylaxis or treatment of GBS infections.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2195055     DOI: 10.1007/bf00917915

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  16 in total

1.  IgG subclasses in human gamma-globulin preparations for intravenous use and their reactivity with staphylococcus protein A.

Authors:  F Skvaril; B Roth-Wicky; S Barandun
Journal:  Vox Sang       Date:  1980       Impact factor: 2.144

2.  Immunospecificity and quantitation of an enzyme-linked immunosorbent assay for group B streptococcal antibody.

Authors:  B F Anthony; N F Concepcion; S A McGeary; J I Ward; D C Heiner; P Shapshak; R A Insel
Journal:  J Clin Microbiol       Date:  1982-08       Impact factor: 5.948

3.  Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens.

Authors:  G R Siber; P H Schur; A C Aisenberg; S A Weitzman; G Schiffman
Journal:  N Engl J Med       Date:  1980-07-24       Impact factor: 91.245

4.  Structural studies of a human gamma 3 myeloma protein (Goe) that binds staph protein A.

Authors:  B Recht; B Frangione; E Franklin; E van Loghem
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

5.  Protein A isolated from Staphylococcus aureus after digestion with lysostaphin.

Authors:  J Sjöquist; B Meloun; H Hjelm
Journal:  Eur J Biochem       Date:  1972-09-25

6.  Differences in anti-protein A activity among IgG subgroups.

Authors:  G Kronvall; R C Williams
Journal:  J Immunol       Date:  1969-10       Impact factor: 5.422

7.  Natural infection of man with group A streptococci. Levels; restriction in class, subclass, and type; and clonal appearance of polysaccharide-group-specific antibodies.

Authors:  W F Riesen; F Skvaril; D G Braun
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

8.  Isolation of IgG3 from normal human sera and from a patient with multiple myeloma by using protein A-sepharose 4B.

Authors:  H Hjelm
Journal:  Scand J Immunol       Date:  1975       Impact factor: 3.487

9.  Functional activities of various preparations of human intravenous immunoglobulin against type III group B Streptococcus.

Authors:  K S Kim; C A Wass; J H Kang; B F Anthony
Journal:  J Infect Dis       Date:  1986-06       Impact factor: 5.226

10.  Penicillin tolerance in group B streptococci isolated from infected neonates.

Authors:  K S Kim; B F Anthony
Journal:  J Infect Dis       Date:  1981-11       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.